Phase II Trial of Pegylated Liposomal Doxorubicin (Doxil), Vincristine, and Dexamethasone (DVd) in Combination With Arsenic Trioxide (Trisenox) in Untreated Patients With Symptomatic Multiple Myeloma
Sponsor study identifier
interventional
12
1 country
1
Study Start
July 2004
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
September 2006
Actual (reported)Study Completion
August 2008
Actual (reported)This study will assess the ability of Doxorubicin, Vincristine and Dexamethasone plus arsenic trioxide to achieve an overall response rate of greater than 60%.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 2008
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 2004
Date type not reportedThis date has not been verified as actual or estimated.
September 12, 2005
Actual (reported)September 20, 2005
Actual (reported)September 2006
Actual (reported)August 2008
Actual (reported)Assess the ability of DVd plus arsenic trioxide to achieve an overall response (complete and partial) rate in patients with untreated Multiple myeloma(MM)
2004-2008
40 mg/m2 IV day 1
Ohio State University
Columbus, Ohio, 43210, United States
Hofmeister CC, Jansak B, Denlinger N, Kraut EH, Benson DM, Farag SS. Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma. Leuk Res. 2008 Aug;32(8):1295-8. doi: 10.1016/j.leukres.2007.10.020. Epub 2007 Dec 21.
Craig Hofmeister, MD
Ohio State University
12 participants (actual enrollment reported by the registry).
First Submitted
September 12, 2005
First Posted
September 20, 2005
Study Start
July 2004
Date type not reportedThis date has not been verified as actual or estimated.
40 mg PO days 1-4
0.25 mg/kg IV over 1-4 hours twice per week, week 1-4 of each cycle (i.e., days 1 and 4; 8 and 11; 15 and 18; 22 and 25)
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
September 2006
Actual (reported)Study Completion
August 2008
Actual (reported)Last Updated
June 10, 2015
Record last verified: 2015-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: